Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2-Reference-Cited by-同舟云学术

Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2

Published:2020-07 Issue: Volume:157 Page:104853
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Habtemariam Solomon^ORCID,Nabavi Seyed Fazel,Ghavami Saeid^ORCID,Cismaru Cosmin Andrei^ORCID,Berindan-Neagoe Ioana,Nabavi Seyed Mohammad

Publisher

Elsevier BV

Subject

Pharmacology

Reference7 articles.

1. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections;Shen;Biochimie,2017

2. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection;Iwata-Yoshikawa;J. Virol.,2019

3. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells;Matsuyama;Proc. Natl. Acad. Sci. U. S. A.,2020

4. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

5. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells;Lukassen;EMBO J.,2020

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acoustofluidic Virus Isolation via Bessel Beam Excitation Separation Technology;ACS Nano;2024-08-12

2. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery;Genes & Diseases;2023-07

3. Bromhexine: Into the spotlight;Viral, Parasitic, Bacterial, and Fungal Infections;2023

4. In Vitro Inhibition of SARS-CoV-2 Infection by Bromhexine hydrochloride;2022-12-26

5. Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial;Journal of Clinical Medicine;2022-12-24